This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mercier, R. C.
Right arrow Articles by Rybak, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mercier, R. C.
Right arrow Articles by Rybak, M. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 06 1997, 1307-1312, Vol 41, No. 6
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium

RC Mercier, HH Houlihan and MJ Rybak
Department of Pharmacy Services, Detroit Receiving Hospital/University Health Center and College of Pharmacy and Allied Health Professions, Wayne State University, Michigan 48201, USA.

The objectives of the present study were to compare the in vitro activity of LY333328 (LY) to that of vancomycin (V) alone and in combination with gentamicin (G) and rifampin (R) against methicillin- resistant Staphylococcus aureus (MRSA) and V-resistant Enterococcus faecium (VREF), by using the killing curve methods. In addition, the effect of the inoculum size and protein on LY's activity was evaluated by using MICs and killing curves. MICs, MBCs, and killing curves were determined with supplemented Mueller-Hinton broth (B), B with albumin (4 g/dl) (A), and B with 50% pooled human serum (S). For MRSA, time to 99.9% killing after exposure to LY at four times the MIC (4x MIC) was achieved at 0.5 +/- 0 h (mean +/- standard deviation) and was significantly faster than that by V (8.54 +/- 0.10 h; P = 0.001). Against VREF, LY decreased the inoculum by 2.2 log10 CFU/ml at 24 h (P = 0.002). With a large inoculum of MRSA, the activity of LY and V at 4x MIC was decreased compared to that with the standard inoculum (P = 0.0003) and regrowth occurred at 24 h. The reduction in the number of CFU per milliliter at 24 h to 2 log10 CFU/ml was restored by increasing the LY concentration to at least 16x MIC. At 24 h, the combinations of LY and G, LY and R, LY and V, and V and G were better than either LY or V alone against a large inoculum of MRSA (P = 0.0002). LY and G achieved 99.9% killing at 1.01 +/- 0.03 h and was more rapid (P < 0.007) than all the other regimens studied except for V and G, which achieved 99.9% killing at 3.59 +/- 0.01 h. Killing curves determined with different media against a standard inoculum of MRSA did not demonstrate a significant difference between LY and V at 24 h. Time to 99.9% killing was more rapid with LY than with V in B, A, and S (P = 0.0002). Times to 99.9% killing by LY in B, A, and S were not significantly different from each other. Against VREF, LY killed better than V in B, A, or S at 24 h (P = 0.0002). LY in B was more active than LY in A or S (P = 0.0002). LY is a new potent glycopeptide with a unique activity profile. It has a greater activity than that of V against MRSA and has activity against VREF. LY demonstrated synergism in combination with gentamicin against MRSA. LY was affected by large inoculum sizes and proteins in time-kill studies. However, the effect was compensated for by increasing the drug concentration to 16x MIC.


This article has been cited by other articles:

  • McKay, G. A., Beaulieu, S., Arhin, F. F., Belley, A., Sarmiento, I., Parr, T. Jr, Moeck, G. (2009). Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 63: 1191-1199 [Abstract] [Full Text]  
  • Nguyen, H. A., Denis, O., Vergison, A., Tulkens, P. M., Struelens, M. J., Van Bambeke, F. (2009). Intracellular Activity of Antibiotics in a Model of Human THP-1 Macrophages Infected by a Staphylococcus aureus Small-Colony Variant Strain Isolated from a Cystic Fibrosis Patient: Study of Antibiotic Combinations. Antimicrob. Agents Chemother. 53: 1443-1449 [Abstract] [Full Text]  
  • Perlroth, J., Kuo, M., Tan, J., Bayer, A. S., Miller, L. G. (2008). Adjunctive Use of Rifampin for the Treatment of Staphylococcus aureus Infections: A Systematic Review of the Literature. Arch Intern Med 168: 805-819 [Abstract] [Full Text]  
  • Cabellos, C., Fernandez, A., Maiques, J. M., Tubau, F., Ardanuy, C., Viladrich, P. F., Linares, J., Gudiol, F. (2003). Experimental Study of LY333328 (Oritavancin), Alone and in Combination, in Therapy of Cephalosporin-Resistant Pneumococcal Meningitis. Antimicrob. Agents Chemother. 47: 1907-1911 [Abstract] [Full Text]  
  • Boylan, C. J., Campanale, K., Iversen, P. W., Phillips, D. L., Zeckel, M. L., Parr, T. R. Jr. (2003). Pharmacodynamics of Oritavancin (LY333328) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus Infection. Antimicrob. Agents Chemother. 47: 1700-1706 [Abstract] [Full Text]  
  • Mercier, R.-C., Stumpo, C., Rybak, M. J. (2002). Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium. J Antimicrob Chemother 50: 19-24 [Abstract] [Full Text]  
  • Coyle, E. A., Rybak, M. J. (2001). Activity of Oritavancin (LY333328), an Investigational Glycopeptide, Compared to That of Vancomycin against Multidrug-Resistant Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 45: 706-709 [Abstract] [Full Text]  
  • Aeschlimann, J. R., Allen, G. P., Hershberger, E., Rybak, M. J. (2000). Activities of LY333328 and Vancomycin Administered Alone or in Combination with Gentamicin against Three Strains of Vancomycin-Intermediate Staphylococcus aureus in an In Vitro Pharmacodynamic Infection Model. Antimicrob. Agents Chemother. 44: 2991-2998 [Abstract] [Full Text]  
  • Cetinkaya, Y., Falk, P., Mayhall, C. G. (2000). Vancomycin-Resistant Enterococci. Clin. Microbiol. Rev. 13: 686-707 [Abstract] [Full Text]  
  • Zelenitsky, S. A., Booker, B., Laing, N., Karlowsky, J. A., Hoban, D. J., Zhanel, G. G. (1999). Synergy of an Investigational Glycopeptide, LY333328, with Once-Daily Gentamicin against Vancomycin-Resistant Enterococcus faecium in a Multiple-Dose, In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 43: 592-597 [Abstract] [Full Text]  
  • Ostrowsky, B., Eliopoulos, G. M. (1999). Analytic Reviews : Enterococcal Infections: Resistance Mechanisms, Treatment Strategies, and Hospital Issues: Ostrowsky B, Eliopoulos, GM Enterococcal Infections Resistance Mechanisms, Treatment Strategies, and Hospital Issues J Intensive Care Med 1999,14.62-73. J Intensive Care Med 14: 62-73  
  • Saleh-Mghir, A., Lefort, A., Petegnief, Y., Dautrey, S., Vallois, J.-M., Le Guludec, D., Carbon, C., Fantin, B. (1999). Activity and Diffusion of LY333328 in Experimental Endocarditis Due to Vancomycin-Resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 43: 115-120 [Abstract] [Full Text]  
  • Zhanel, G. G., Kirkpatrick, I. D. C., Hoban, D. J., Kabani, A. M., Karlowsky, J. A. (1998). Influence of Human Serum on Pharmacodynamic Properties of an Investigational Glycopeptide, LY333328, and Comparator Agents against Staphylococcus aureus. Antimicrob. Agents Chemother. 42: 2427-2430 [Abstract] [Full Text]  
  • García-Garrote, F., Cercenado, E., Alcalá, L., Bouza, E. (1998). In Vitro Activity of the New Glycopeptide LY333328 against Multiply Resistant Gram-Positive Clinical Isolates. Antimicrob. Agents Chemother. 42: 2452-2455 [Abstract] [Full Text]  
  • Kaatz, G. W., Seo, S. M., Aeschlimann, J. R., Houlihan, H. H., Mercier, R.-C., Rybak, M. J. (1998). Efficacy of LY333328 against Experimental Methicillin-Resistant Staphylococcus aureus Endocarditis. Antimicrob. Agents Chemother. 42: 981-983 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»